Hormones, vitamins, and growth factors in cancer treatment and prevention: A critical appraisal

Cancer

Volumn 78, Issue 11, 1996, Pages 2264-2280

  Lupulescu, Aurel P ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

adjuvant systemic therapy; cancer prevention; growth factors; hormone antagonists; hormones; vitamins

Indexed keywords

ALPHA TOCOPHEROL; ANDROGEN; ANGIOPEPTIN; ANTIANDROGEN; ANTIESTROGEN; ANTIGESTAGEN; AROMATASE INHIBITOR; ASCORBIC ACID; BETA CAROTENE; CORTICOSTEROID; CYPROTERONE ACETATE; CYTOKINE; ESTROGEN; GESTAGEN; GONADORELIN AGONIST; GROWTH FACTOR; HORMONE RECEPTOR; MEDROXYPROGESTERONE ACETATE; MIFEPRISTONE; OCTREOTIDE; RETINOL; SEOCALCITOL; SURAMIN; TAMOXIFEN; THYROID HORMONE; UNINDEXED DRUG; VAPREOTIDE; VITAMIN B GROUP; VITAMIN D; VITAMIN D DERIVATIVE; VITAMIN K GROUP;

ACNE; ARTICLE; BREAST CARCINOMA; CANCER PREVENTION; CARCINOGENESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENDOMETRIUM CARCINOMA; FEMALE; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HIRSUTISM; HORMONE SUBSTITUTION; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS; NONHUMAN; ORAL DRUG ADMINISTRATION; ORCHIECTOMY; OSTEOPOROSIS; OVARY CARCINOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CARCINOMA; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TOPICAL DRUG ADMINISTRATION; VEIN THROMBOSIS;

ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; CELL DIVISION; CYTOKINES; GROWTH SUBSTANCES; HORMONES; HUMANS; NEOPLASMS; NEOPLASMS, HORMONE-DEPENDENT; VITAMINS;

EID: 0029802704     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19961201)78:11<2264::AID-CNCR2>3.0.CO;2-N     Document Type: Article

References (131)

1. Lupulescu A. Hormones and carcinogenesis. New York: Praeger Scientific, 1983:312-43.
2. Lupulescu A. Hormones and vitamins in cancer treatment. Boca Raton and Boston: CRC Press, 1990:33-90.
3. Henderson BE, Ross RK, Pike MC. Hormonal chemoprevention of cancer in women. Science 1993;259:633-8.
4. Huggins C. Endocrine-induced regression of cancers. Science 1967;156:1050-4.
5. Stähelin HB. Vitamins and cancer. Recent Results Cancer Res 1988;108:227-34.
6. Lippman SM, Benner SE, Hong WK. Cancer chemoprevention. J Clin Oncol 1994;12:851-73.
7. Lupulescu A. The role of vitamins A, β-carotene, E and C in cancer cell biology. Int J Vitam Nutr Res 1994;64:3-14.
8. Greig R, Dunnington D, Murthy U, Anzano M. Growth factors as novel therapeutic targets in neoplastic disease. Cancer Surv 1988;7:653-74.
9. Garner A. Therapeutic potential of growth factors and their antagonists. Yale J Biol Med 1992;65:715-23.
10. Myers C, Trepel J, Sartor O, Cooper M, Ranson M, Toko T, et al. Antigrowth factor strategies. Cancer 1993;71:1172-8.
11. Jensen EV, DeSombre ER. Estrogen-receptor interaction. Science 1973;182:126-34.
12. Lacassagne A. Apparition de cancers de la mammelle chez la souris mâle, soumise à des injections de folliculine. C R Acad Sci 1932;195:630-2.
13. Lupulescu A. Estrogen use and cancer incidence. Cancer Invest 1995;13:287-95.
14. Lacassagne A, Raynaud A. Sur le mécanisme d'une action préventive de la testostérone sur le carcinome mammaire de la souris. C R Seances Soc Biol Fil 1939;131:586-8.
15. Kennedy BJ. Hormone therapy in cancer. Geriatrics 1970; 25:106-12.
16. Bagatell CJ, Bremner WJ. Androgens in men: uses and abuses. N Engl J Med 1996;334:707-14.
17. 2) LHRH ethylamide in stage C and D prostate cancer: today's therapy of choice: rationale and 5-year clinical experience. Prog Clin Biol Res 1988;262:11-63.
18. Dreicer R, Wilding G. Steroid hormone agonists and antagonists in the treatment of cancer. Cancer Invest 1992;10:27-41.
19. Rittmaster RS. Finasteride. N Engl J Med 1994;330:120-5.
20. Furr BJ. Casodex: preclinical studies and controversies. Ann N Y Acad Sci 1995;761:79-96.
21. Denis L, Murphy GP. Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer 1993;72(Suppl. 12):3888-95.
22. Wingfield M. The daughters of stilbestrol. BMJ 1991; 302:1991-2.
23. Colton T, Greenberg R, Noller K, Resseguie L, Bennekom C, Heeren T, et al. Breast cancer in mothers prescribed diethyl-stilbestrol in pregnancy. JAMA 1993;269:2096-100.
24. Huggins C, Moon R, Morii S. Extinction of experimental mammary cancer. I. Estradiol 17β and progesterone. Proc Natl Acad Sci U S A 1962;48:379-86.
25. Smith PH. Hormone therapy: an overview. Cancer Surv 1995;23:171-81.
26. Jordan VC. Overview from the international conference on long-term tamoxifen therapy for breast cancer. J Natl Cancer Inst 1992;84:231-4.
27. 8-cholestenol conversion to lathosterol in women with breast cancer. J Clin Oncol 1995;13:2900-5.
28. Van Leeuwen FE, Benraadt J, Coebergh JW, Kiemeney LA, Gimbrère CH, Otter R, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994;343:448-52.
29. Nayfield SG, Karp JE, Ford LG, Dorr FA, Kramer BS. Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 1991;83:1450-9.
30. Friedman MA, Trimble EL, Abrams JS. Tamoxifen: trials, tribulations, and trade-offs. J Natl Cancer Inst 1994;86:478-9.
31. Marshall E. Long-term tamoxifen trial halted. Science 1995;270:1562.
32. Valavaara R, Tuominen J, Johansson R. Predictive value of tumor estrogen and progesterone receptor levels in postmenopausal women with advanced breast cancer treated with toremifene. Cancer 1990;66:2264-9.
33. Ke HZ, Simmons HA, Pirie CM, Crawford DT, Thompson DD. Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats. Endocrinology 1995;136:2435-41.
34. Wolf DM, Fuqua SA. Mechanisms of action of antiestrogens. Cancer Treat Rev 1995;21:247-71.
35. Muss HB, Case LD, Capizzi RL, Cooper MR, Cruz J, Jackson D, et al. High- versus standard-dose megestrol acetate in women with advanced breast cancer: a phase III trial of the Piedmont Oncology Association. J Clin Oncol 1990;8:1797-1805.
36. Schacter L, Rozencweig M, Canetta R, Kelley S, Nicaise C, Smaldone L. Megestrol acetate: clinical experience. Cancer Treat Rev 1989;16:49-63.
37. Glauber JG, Kiang DT. The changing role of hormonal therapy in advanced breast cancer. Semin Oncol 1992;19:308-16.
38. Baulieu EE. RU-486 as an antiprogesterone steroid. JAMA 1989;262:1808-14.
39. Mainwaring WI. Hormones and cancer. In: Franks LM, Teich NM. Introduction to the cellular and molecular biology of cancer. Oxford: Oxford Medical Publications, 1991:357-85.
40. Santen RJ. Suppression of estrogens with aminoglutethimide and hydrocortisone (medical adrenalectomy) as treatment of advanced breast carcinoma. Breast Cancer Res Treat 1981;1:183-202.
41. Lipton A, Harvey HA, Demers LM, Hanagan JR, Mulagha MT, Kochak GM. A phase I trial of CGS16949A. A new aromatase inhibitor. Cancer 1990;65:1279-85.
42. Miller WR. Aromatase inhibitors: where are we now? Br J Cancer 1996;73:415-7.
43. Pearson OH, Eliel LP, Rawson RW, Dobriner K, Rhoads CP. ACTH and cortisone-induced regression of lymphoid tumors in man. Cancer 1949;2:943-5.
44. Thorner MO, Vance ML, Horvath E, Kovacs K. The anterior pituitary. In: Wilson JD, Foster DW, editors. William's textbook of endocrinology. 8th edition. Philadelphia: W.B. Saunders, 1992:221-310.
45. Reichlin S. Somatostatin. N Engl J Med 1983;309:1495-501.
46. Fløgstad AK, Halse J, Haldorsen T, Lancranjan I, Marbach P, Bruns CH, et al. Sandostatin LAR in acromegalic patients: a dose-range study. J Clin Endocrinol Metab 1995;80:3601-7.
47. Lamberts SW, Van der Lely A-J, de Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996;334:246-54.
48. Danforth DN, Tamarkin L, Mulvihill JJ, Bagley CS, Lippman ME. Plasma melatonin and the hormone-dependency of human breast cancer. J Clin Oncol 1985;3:941-8.
49. Smith MA, Parkinson DR, Cheson BD, Friedman MA. Retinoids in cancer therapy. J Clin Oncol 1992;10:839-64.
50. Warrell RP, Frankel SR, Miller WH, Gabrilove J, Gordon M, Dmitrovsky E, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 1991;324:1385-93.
51. Van Poppel G. Carotenoids and cancer: an update with emphasis on human intervention studies. Eur J Cancer 1993;29:1335-44.
52. Moertel CG, Fleming TR, Creagan ET, Rubin J, O'Connell MJ, Ames MM. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy: a randomized double-blind comparison. N Engl J Med 1985;312:137-41.
53. Herbert V. The antioxidant supplement myth. Am J Clin Nutr 1994;60:157-8.
54. Bollag W, Hartmann HR. Prevention and therapy of cancer with retinoids in animals and man. Cancer Surv 1983;2:293-314.
55. Tangrea JA, Edwards BK, Taylor PR, Hartman AM, Peck GL, Salasche SJ, et al. Long-term therapy with low-dose isotretinoin for prevention of basal cell carcinoma: a multicenter clinical trial. J Natl Cancer Inst 1992;84:328-32.
56. Lippman SM, Kessler JF, Meyskens FL. Retinoids as preventive and therapeutic anticancer agents. Cancer Treat Rep 1987;71:493-515.
57. Pandolfi PP, Grignani F, Alcalay M, Biondi A, LoCoCo F, Pelicci PG. Structure and origin of the acute promyelocytic leukemia myl/RARαcDNA and characterization of its retinoid-binding and transactivation properties. Oncogene 1991;6:1285-92.
58. Pastorino U, Infante M, Maioli M, Chiesa G, Buyse M, Firket P, et al. Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clin Oncol 1993;11:1216-22.
59. Costa A, Formelli F, Chiesa F, Decensi A, DePalo G, Veronesi U. Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide. Cancer Res 1994;54(Suppl.): 2032S-2037S.
60. Hunter DJ, Manson JE, Colditz GA. A prospective study of the intake of vitamins C, E, and A and the risk of breast cancer. N Engl J Med 1993;329:234-40.
61. Cuzick J, DeStavola BL, Russell MJ, Thomas BS. Vitamin A, Vitamin E and the risk of cervical intraepithelial neoplasia. Br J Cancer 1990;62:651-2.
62. Heinonen OP, Huttunen JK, Albanes D. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994;330:1029-35.
63. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996;334:1150-5.
64. Ziegler RG, Colavito EA, Hartge P, McAdams MJ, Schoenberg JB, Mason TJ, et al. Importance of α-carotene, β-carotene, and other phytochemicals in the etiology of lung cancer. J Natl Cancer Inst 1996;88:612-5.
65. Singh VN, Gaby SK. Premalignant lesions: role of antioxidant vitamins and β-carotene in risk reduction and prevention of malignant transformation. Am J Clin Nutr 1991;53(Suppl.) :386-90.
66. Eichholzer M, Stähelin HB, Gey KF, Ludin E, Bernasconi F. Prediction of male cancer mortality by plasma levels of interacting vitamins: 17-year follow-up of the prospective Basel study. Int J Cancer 1996;66:145-50.
67. Li J-Y, Taylor PR, Li B, Dawsey S, Wang G-Q, Ershow AG, et al. Nutrition intervention trials in Linxian, China: multiple vitamin/mineral supplementation, cancer incidence, and disease-specific mortality among adults with esophageal dysplasia. J Natl Cancer Inst 1993;85:1492-8.
68. Jäger E, Klein O, Wächter B, Müller B, Braun U, Knuth A. Second-line treatment with high-dose 5-fluorouracil and folinic acid in advanced colorectal cancer refractory to standard-dose 5-fluorouracil treatment. Oncology 1995;52:470-3.
69. Hanck AB. Vitamin C and cancer. Prog Clin Biol Res 1988;259:307-20.
70. Schwartz J, Shklar G, Trickier D. Vitamin C enhances the development of carcinomas in the hamster buccal pouch experimental model. Oral Surg Oral Med Oral Pathol 1993;76:718-22.
71. Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of cancer: prolongation of survival times in the terminal human cancer. Proc Natl Acad Sci U S A 1976;73:3685-9.
72. Block G. Vitamin C status and cancer: epidemiologic evidence of reduced risk. Ann N Y Acad Sci 1992;669:280-90.
73. Byers T, Guerrero N. Epidemiologic evidence for vitamin C and vitamin E in cancer prevention. Am J Clin Nutr 1995;62(Suppl.):1385-92.
74. Feldman D, Skowronski RJ, Peehl DM. Vitamin D and prostate cancer. Adv Exp Med Biol 1995;375:53-63.
75. Colston KW, MacKay AG, James SY, Binderup L, Chander S, Coombes RC. EB1089: a new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro. Biochem Pharmacol 1992;44:2273-80.
76. Knekt P. Vitamin E and cancer: epidemiology. Ann N Y Acad Sci 1992;669:269-76.
77. Chlebowski RT, Akman SA, Block JB. Vitamin K in the treatment of cancer. Cancer Treat Rev 1985;12:49-63.
78. Golding J, Greenwood R, Birmingham K, Mott M. Childhood cancer, intramuscular vitamin K, and pethidine given during labour. BMJ 1992;305:341-6.
79. Klebanoff MA, Read JS, Mills JL, Shiono PH. The risk of childhood cancer after neonatal exposure to vitamin K. N Engl J Med 1993;329:905-8.
80. Aaronson SA. Growth factors and cancer. Science 1991; 254:1146-53.
81. Folkman J. Peptides under study. J Natl Cancer Inst 1994; 86:742-3.
82. Banks RE, Patel PM, Selby PJ. Interleukin 12: a new clinical player in cytokine therapy. Br J Cancer 1995;71:655-9.
83. Clark JW, Chabner BA. Suramin and prostate cancer: where do we go from here? J Clin Oncol 1995;13:2155-7.
84. De Voogt HJ, Rao BR, Geldof AA. How to define hormone resistance. Prog Clin Biol Res 1989;303:325-9.
85. Kerr JF, Winterford CM, Harmon BV. Apoptosis: its significance in cancer and cancer therapy. Cancer 1994;73:2013-26.
86. Haussler MR, Mangelsdorf DJ, Komm BS, Terpening CM, Yamaoka K, Allegretto EA, et al. Molecular biology of the vitamin D hormone. Recent Prog Horm Res 1988;44:263-305.
87. Evans RM. The steroid and thyroid hormone receptor superfamily. Science 1988;240:889-93.
88. Prabhala RH, Garewal HS, Hicks MJ, Sampliner RE, Watson RR. The effects of 13-cis-retinoic acid and beta-carotene on cellular immunity in humans. Cancer 1991;67:1556-60.
89. 6. In: Machlin LJ, editor. Handbook of vitamins. 2nd edition. New York: M. Dekker, 1991:341-92.
90. Gershoff SN. Vitamin C (ascorbic acid): new roles, new requirements. Nutr Rev 1993;51:313-26.
91. Hewison M. Vitamin D and the immune system. J Endocrinol 1992;132:173-5.
92. Redpath NT, Proud CG. Molecular mechanisms in the control of translation by hormones and growth factors. Biochim Biophys Acta 1994;1220:147-62.
93. Sorrentino V. Growth factors, growth inhibitors and cell cycle control. Anticancer Res 1989;9:1925-36.
94. Preston-Martin S, Pike MC, Ross RK, Jones PA, Henderson BE. Increased cell division as a cause of human cancer. Cancer Res 1990;50:7415-21.
95. Weinberg RA. Oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis. Cancer Res 1989;49:3713-21.
96. Lupulescu A. Control of precancer cell transformation into cancer cells: its relevance to cancer prevention. Cancer Det Prev. In press.
97. Cohen SM, Ellwein LB. Genetic errors, cell proliferation, and carcinogenesis. Cancer Res 1991;51:6493-505.
98. Broxmeyer H. The cell cycle as therapeutic target. Cancer Invest 1995;13:617-24.
99. Mastrangelo MJ, Berd D, Nathan FE, Lattime EC. Gene therapy for human cancer: an essay for clinicians. Semin Oncol 1996;23:4-21.
100. Van Leeuwen FE, Rookus MA. The role of exogenous hormones in the epidemiology of breast, ovarian, and endometrial cancer. Eur J Cancer Clin Oncol 1989;25:1961-72.
101. Nachtigall MJ, Smilen SW, Nachtigall RD, Nachtigall RH, Nachtigall LE. Incidence of breast cancer in a 22-year study of women receiving estrogen-progestin replacement therapy. Obstet Gynecol 1992;80:827-30.
102. Jacobs HS, Loeffler FE. Postmenopausal hormone replacement therapy. BMJ 1992;305:1403-8.
103. Voigt LF, Weiss NS, Chu J, Daling JR, McKnight B, Van Belle G. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 1991;338:274-7.
104. The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 1996;275:370-5.
105. Godwin AK, Testa JR, Hamilton TC. The biology of ovarian cancer development. Cancer 1993;71:530-6.
106. Prentice RL. Epidemiologic data on exogenous hormones and hepatocellular carcinoma and selected other cancers. Prev Med 1991;20:38-46.
107. Sale GE, Lerner KG. Multiple tumors after androgen therapy. Arch Pathol Lab Med 1977;101:600-3.
108. Tulinius H, Egilsson V, Olafsdóttir GH, Sigvaldason H. Risk of prostate, ovarian and endometrial cancer among relatives of women with breast cancer. BMJ 1992;305:855-7.
109. Collins FS. BRCA1: lots of mutations, lots of dilemmas. N Engl J Med 1996;334:186-8.
110. Brison O. Gene amplification and tumor progression. Biochim Biophys Acta 1993;1155:25-41.
111. Greenwald P, Kelloff G, Burch-Whitman C, Kramer BS. Chemoprevention. CA Cancer J Clin 1995;45:31-49.
112. Fung CY, Fisher DE. p53: from molecular mechanisms to prognosis in cancer. J Clin Oncol 1995;13:808-11.
113. Jordan VC, Lababidi MK, Langan-Fahey S. Suppression of mouse mammary tumorigenesis by long-term tamoxifen therapy. J Natl Cancer Inst 1991;83:492-6.
114. Early Breast Cancer Trialists Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immunotherapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992;339:1-15,71-85.
115. Fisher B, Brown A, Wolmark N, Redmond C, Wickerham DL, Wittliff J, et al. Prolonging tamoxifen therapy for primary breast cancer: findings from the National Surgical Adjuvant Breast and Bowel Project clinical trial. Ann Intern Med 1987;106:649-54.
116. Zimnisky SJ, Warren RC. Induction of tamoxifen-dependent rat mammary tumors. Cancer Res 1993;53:2937-9.
117. Fornander T, Hellström A-C, Moberger B. Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. J Natl Cancer Inst 1993;85:1850-3.
118. Anzano MA, Peer CW, Smith JM, Mullen LT, Shrader MW, Logsdon DL, et al. Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid. J Natl Cancer Inst 1996;88:123-5.
119. Brawer MK, Ellis WJ. Chemoprevention for prostate cancer. Cancer 1995;75:1783-9.
120. Griffiths K, Eaton CL, Harper ME, Turkes A, Peeling WB. Hormonal treatment of advanced disease: some newer aspects. Semin Oncol 1994;21:672-87.
121. Akakura K, Bruchowsky N, Goldenberg S, Rennie P, Buckley A, Sulllivan L. Effects of intermittent androgen suppression on androgen-dependent tumors. Cancer 1993;71:2782-90.
122. Schuchard M, Landers J, Sandhu NP, Spelsberg TC. Steroid hormone regulation of nuclear proto-oncogenes. Endocr Rev 1993;14:659-69.
123. Schwartz AG, Whitcomb JM, Nyce JW, Lewbart ML, Pashko LL. Dehydroepiandrosterone and structural analogs: a new class of cancer chemoprevention agents. Adv Cancer Res 1988;51:391-424.
124. Austoker J. Diet and cancer. BMJ 1994;308:1610-4.
125. Wouters W, Van Dun J, Dillen A, Coene MC, Cools W, DeCoster R. Effects of liarozole, a new antitumoral compound, on retinoic acid-induced inhibition of cell growth and on retinoic acid metabolism in MCF-7 human breast cancer cells. Cancer Res 1992;52:2841-6.
126. Cody V. Pseudovitamins. In: Machlin LJ, editor. Handbook of vitamins. New York M. Dekker, 1991:575-82.
127. Sanders BG, Kline K. Nutrition, immunology and cancer: an overview. Adv Exp Med Biol 1995;369:185-94.
128. Eisenberger MA, Reyno LM. Suramin. Cancer Treat Rev 1994;20:259-73.
129. Ford LG, Brawley OW, Perlman JA, Nayfield SG, Johnson KA, Kramer BS. The potential for hormonal prevention trials. Cancer 1994;74:2726-33.
130. Travis J. Novel anticancer agents move closer to reality [news]. Science 1993;260:1877-8.
131. Sheridan W. Cytokine-only approaches to mobilization of progenitor cells. In: Morstyn G, Sheridan W. Cancer: cell therapy. Cambridge: Cambridge University Press, 1996:146-82.